2017
DOI: 10.1016/j.lungcan.2017.01.019
|View full text |Cite
|
Sign up to set email alerts
|

A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
23
0
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 49 publications
(26 citation statements)
references
References 14 publications
(29 reference statements)
2
23
0
1
Order By: Relevance
“…IPC is becoming a worthy alternative for pleurodesis in symptomatic malignant pleurisy as shown by the TIME2 randomized controlled trial (RCT) comparing IPC with chest tube and talc pleurodesis. 8 Although the primary end point in a 2017 RCT with superiority design was not met, 12 the use of IPC showed to be effective and led to fewer reinterventions and hospital admissions. The efficacy of IPC in inducing pleurodesis could potentially be enhanced by coating these devices with sclerosing agents such as silver nitrate.…”
Section: Discussionmentioning
confidence: 99%
“…IPC is becoming a worthy alternative for pleurodesis in symptomatic malignant pleurisy as shown by the TIME2 randomized controlled trial (RCT) comparing IPC with chest tube and talc pleurodesis. 8 Although the primary end point in a 2017 RCT with superiority design was not met, 12 the use of IPC showed to be effective and led to fewer reinterventions and hospital admissions. The efficacy of IPC in inducing pleurodesis could potentially be enhanced by coating these devices with sclerosing agents such as silver nitrate.…”
Section: Discussionmentioning
confidence: 99%
“…Lastly, the use of IPC to deal with KS-associated chylous effusions has not been reported before. IPC have a proven efficacy and safety in the palliation of malignant pleural effusions, but previous clinical trials excluded patients with impaired immunity and/or chylothorax 28–30. The use of IPCs has not been shown to increase the risk of infection while patients receive chemotherapy 31.…”
Section: Discussionmentioning
confidence: 99%
“…Состав: доксициклин (в форме гидрохлорида) 100 мг, вспомогательные вещества: натрия дисульфит -6 мг, динатрия эдетат -0,02 мг. Кроме антибактериального действия, оказываемого Доксициклином, данное вещество, согласно Национальным клиническим рекомендациям по торакальной хирургии, является препаратом выбора для химического плевродеза [10][11][12]. Выведение из эксперимента проводили на 10-е, 20-е и 30-е сутки эксперимента.…”
Section: дизайн исследованияunclassified